Nagasawa T
Division of Hematology, University of Tsukuba.
Rinsho Ketsueki. 1993 May;34(5):551-6.
Chronic myeloproliferative disorders (CMPD) consisted of the disease with chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF) and other proliferative diseases have commonly developed increased megakaryocytes. Recently, clonal assay for megakaryocytic progenitors, identification of young megakaryocytes and isolation of megakaryocytes have been greatly facilitated an analysis of megakaryopoeisis. It is still difficult quantitatively and serially to estimate megakaryopoiesis in CMPD. However, number of CFU-Meg, number of megakaryocytes (PGPIIb/IIIb) in the clot section, cytoplasmic area and DNA content of megakaryocytes were measurable in the clinical materials. The present lecture has been focused to following points; 1) megakaryopoiesis in CML, 2) differences of megakaryopoiesis between ET and PV, 3) megakaryopoiesis in Ph1 positive ET, and 4) megakaryopoiesis in rective thrombocytosis by our data and previous studies.
慢性骨髓增殖性疾病（CMPD）包括慢性粒细胞白血病（CML）、真性红细胞增多症（PV）、原发性血小板增多症（ET）、骨髓纤维化（MF）以及其他增殖性疾病，这些疾病通常会出现巨核细胞增多。近来，巨核细胞祖细胞的克隆分析、幼巨核细胞的鉴定以及巨核细胞的分离极大地促进了对巨核细胞生成的分析。在CMPD中，仍然难以对巨核细胞生成进行定量和连续评估。然而，在临床材料中可测量CFU-Meg的数量、凝块切片中巨核细胞（血小板糖蛋白IIb/IIIb）的数量、巨核细胞的胞质面积和DNA含量。本次讲座聚焦于以下几点：1）CML中的巨核细胞生成；2）ET和PV之间巨核细胞生成的差异；3）Ph1阳性ET中的巨核细胞生成；4）根据我们的数据和以往研究对反应性血小板增多症中的巨核细胞生成进行探讨。
